Wednesday, July 2, 2025

Biogen Wins Approval with FDA for Alzheimer’s Drug

This morning Biogen (NASDAQ:BIIB) received approval from the FDA for their Alzheimer’s drug aducanumab. The FDA decision marks the first new Alzheimer’s disease drug since 2003 to receive approval and the first that aims to slow disease progression.

The drug aims to remove sticky deposits of a protein called amyloid-beta from the brains of patients in earlier stages of Alzheimer’s. The goal of the drug is to stave off its ravages, which include memory loss and the ability to care for one’s self.

The FDA decision was originally supposed to land in March, but was extended in January for additional review. The early data on the drug showed mixed results with some doctors saying clinical trial results were inconsistent and further confirmation was needed.

Before this decision landed, J.P. Morgan analyst Cory Kasimov called the FDA’s decision “the mother of all binary events.”

The stock is currently halted and last traded at $286.43


Information for this briefing was found via the FDA, Biogen, JP Morgan, and Reuters. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Gold Drilling Scaled to 60,000 Meters: How Big Can This Get? | Roger Rosmus – Goliath Resources

Baselode Energy To Acquire Forum Energy: The Merger Of Equals Deal

TriStar Gold: The Revised Castelo de Sonhos Prefeasibility Study

Recommended

ESGold To Expand Mine Building At Montauban In Advance Of Gold & Silver Production

Goliath Resources Expands 2025 Drill Program To 60,000 Metres

Related News

FDA Releases Guidance for Psychedelic Drug Trials With Possibility of Removing Schedule I Classification

The U.S. Food and Drug Administration (FDA) has released a groundbreaking draft guidance to provide...

Tuesday, June 27, 2023, 03:03:00 PM

Biogen Pays $900 Million To Settle Kickback Lawsuit

Biogen, Inc (NASDAQ: BIIB) has reached a US$900 million deal to resolve a long-running whistleblower...

Friday, July 22, 2022, 09:38:00 AM

Mass Layoffs Hit FDA, CDC and Other Health Agencies

The Trump administration has initiated sweeping layoffs at key US health agencies, with approximately 10,000...

Wednesday, April 2, 2025, 02:19:00 PM

Revive Files Clinical Trial Application With Health Canada, Releases Phase 3 FDA Study Design For Potential Treatment Of COVID-19

Revive Therapeutics (CSE: RVV) continues to advance its clinical trial efforts. The company announced this...

Wednesday, June 3, 2020, 11:30:38 AM

Biogen Sees Two Long-Time Directors Announce Retirement

Biogen Inc (NASDAQ: BIIB) appears to be facing issues related to its executive team. The...

Monday, January 31, 2022, 08:38:57 AM